Menu
← Oncology Approval Tracker
FDA DECISION ·
Ibrance + aromatase inhibitor
palbociclib plus an aromatase inhibitor · Pfizer
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adds pre- and perimenopausal women to initial endocrine-based use with an aromatase inhibitor in HR-positive, HER2-negative advanced or metastatic breast cancer.
LAMPGEN ANALYSIS
Why it matters
The expanded population brings this labeled regimen to additional patients with earlier menopausal status.
What research teams should watch
Document menopausal status, the aromatase inhibitor, and any required ovarian suppression in the regimen plan.
PRIMARY RECORDS